Memo To File: How US FDA Decided Which Janssen Vaccine Drug Substance Batches Were OK To Use

 
• By Bowman Cox

Two batches were authorized because they were made before production waste jammed Emergent BioSolutions' Bayview plant.

Janssen COVID vaccine
fda bares thinking on vaccine drug substance cross-contamination issue

More from Manufacturing

More from Compliance